Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2016

View Archived Issues

BL-84, a genetically optimized banana lectin for influenza

FVM-04 neutralizes EBOV and SUDV in animal models

FDA accepts NanoCor's IND for Carfostin

Hummingbird Bioscience and Sanofi collaborate to develop therapeutic antibodies for cancer

Classic galactosemia animal model mimics human cerebral ataxia symptoms

Chugai Pharmaceutical updates pipeline activities of first quarter 2016

H. Lundbeck patents PDE1 inhibitors

RespiVert and Topivert Pharma disclose p38 kinase inhibitors

GlaxoSmithKline and New York University describe antiprotozoal agents

New probiotic reverses minimal hepatic encephalopathy

Alligator Bioscience receives milestone payment from Johnson & Johnson for ADC-1013 project

hVIVO reports favorable initial data from phase IIa study of PrEP-001 in influenza

Ascentage and Unity Biotechnology collaborate on senolytic therapies for age-related disease

Clusterin shows promise as a therapeutic target and biomarker in osteoporosis

FDA accepts for review Lundbeck's NDA resubmission for intravenous carbamazepine

Allergan acquires Topokine Therapeutics

Immune Therapeutics signs letter of intent to acquire Chinese CAR-T cocktail therapy

Sobi exercises IL-1 licensing agreement option with Affibody

Cold Spring Harbor Laboratory launches Center for Therapeutics Research project

E.U. grant supports PRECIOUS consortium's work on immunotherapeutic nanomedicines

NICE final guidance recommends use of cabazitaxel in England

Patiromer MAA submitted in E.U.

First joint research projects announced under NYU Langone and Technion collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...